PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS shows 3-year equivalent durability in OA Canine Study, page-35

  1. 1,079 Posts.
    lightbulb Created with Sketch. 269
    Hey Mozz

    I know you are busy but you didn't get around to commenting on the competition to paradigm you got to see at OARSI.

    Would still love to hear where our leading competition is at, the pros/cons of their lead drug and also the timelines in regards to getting their drugs to market...

    Thanks in advance
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.